Abstract:The clinical benefits of current antioxidant therapy for Alzheimer's disease (AD) are limited due to their poor disease target specificity. Our long-term objective is thus to design target-specific antioxidants and better understand their pharmacological mechanisms for AD and other human diseases, based on an emerging “pharmacophore conjugation” concept for drug development. The specific hypothesis for this studyl is that amyloid-targeting antioxidants assume targeted interdictions against cerebral Aβ amyloid pathology. We have rationally designed, synthesized, and characterized a novel bifunctional antioxidant- XH2A with chemically conjugated amyloid binding (benzothiazole) and antioxidant (lipoate) moieties. We have performed in sillico, cell culture and animal studies to characterize its partial pharmacological properties. In sillico, cellular, and animal studies on XH2A indicated that: (i) XH2A molecule has only one NH group (<5 hydrogen-bond donors), two N and one O atoms (<10 hydrogen bond acceptors), MW=414 (<500). It agrees well with the general Lipinski's Rule of Five; (ii) XH2A interacts with Aβ1-40 peptide computationally and has an affinity binding constant of KD=4.43 μM toward monomeric Aβ1-40 peptide as determined by the SPR (surface plasmon resonance) technique; (iii) XH2A has no neurotoxicity at low micromolar concentrations, and it interdicted amyloid precursor protein (APP) translation (via its 5'UTR, IC50=50 nM) in human SH-SY5Y cells and attenuated cerebral Aβ amyloid pathology in PS1/APP doubly transgenic mice without inducing apparent animal toxicity and behavior disturbances; (iv) BBB penetration studies indicated that XH2A brain concentration can reach 16 nM (via oral route, a single gavage dose of 25 mg/kg) in mouse brain in just 2 hours. This is approximately 32% of its IC50=50 nM, and its brain to plasma concentration ratio is around 1:2. XH2A interdicts Alzheimer's Aβ amyloidosis both in vitro and in vivo. Thus, XH2A could be a novel brain-permeable antioxidant targeting Alzheimer's amyloidosis.

Biological effects and mechanism of β-amyloid aggregation inhibition by penetrable recombinant human HspB5-ACD structural domain protein

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Rescue of Cognitive Deficits in APP/PS1 Mice by Accelerating the Aggregation of Β-Amyloid Peptide

β-Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling

Impact of Alternating Amino Acid Sequences on Beta-Amyloid-induced Neurotoxicity and Neuroinflammation in Alzheimer's Disease.

Structural Optimization and Biological Evaluation of Substituted Bisphenol A Derivatives As Beta-Amyloid Peptide Aggregation Inhibitors.

Advances in the β-amyloid precursor protein of Alzheimer's disease

Intracellular A beta and its Pathological Role in Alzheimer's Disease: Lessons from the Cellular to Animal Model

P1-385: Protection against beta-amyloid-induced synaptic impairments via promotion of beta-amyloid oligomer aggregation by bis(heptyl)-cognitin

Proteomic Analysis Reveals Physiological Activities of Aβ Peptide for Alzheimer's Disease

Ganoderic Acid A Promotes Amyloid-β Clearance (In Vitro) and Ameliorates Cognitive Deficiency in Alzheimer’s Disease (Mouse Model) Through Autophagy Induced by Activating Axl

Inhibiting Β-Amyloid-associated Alzheimer’s Pathogenesis in Vitro and in Vivo by a Multifunctional Dimeric Bis(12)-hupyridone Derived from Its Natural Analogue

Inhibition of Amyloid Β Aggregation and Cytotoxicity by Berbamine Hydrochloride.

The mechanism for heme to prevent Aβ 1–40 aggregation and its cytotoxicity

A BBB-permeable Antioxidant Targeting Alzheimer's Amyloidogenesis

Molecular Integrative Study on Inhibitory Effects of Pentapeptides on Polymerization and Cell Toxicity of Amyloid-β Peptide (1–42)

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer’s Disease Therapeutic Antibodies

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer's Disease Therapeutic Antibodies.

Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer's disease.

Alleviation of Symptoms of Alzheimer's Disease by Diminishing Aβ Neurotoxicity and Neuroinflammation.